Bridgewater, N.J.-based medical technology company Valeritas Holdings Inc. said it attracted a $21 million investment in the company.

Valeritas, which is developing technologies to treat patients with type 2 diabetes in the U.S. and China, said Chicago-based investment firm Aspire Capital Fund LLC agreed to purchase $21 million worth of the company's stock over a 30-month period.

Aspire Capital has already bought 791,557 shares of the company for $1.2 million following the agreement.